Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Analysts at HC Wainwright issued their FY2024 EPS estimates for Protalix BioTherapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of $0.01 for the year. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q4 2024 earnings at $0.06 EPS and FY2025 earnings at $0.19 EPS.
Separately, StockNews.com lowered shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Tuesday.
Read Our Latest Analysis on PLX
Protalix BioTherapeutics Price Performance
Protalix BioTherapeutics stock traded up $0.02 during trading hours on Wednesday, reaching $2.69. The company had a trading volume of 914,329 shares, compared to its average volume of 727,310. The firm has a market cap of $198.06 million, a price-to-earnings ratio of -20.69 and a beta of 0.75. Protalix BioTherapeutics has a 12-month low of $0.82 and a 12-month high of $2.76. The company has a 50-day moving average price of $2.03 and a 200 day moving average price of $1.44.
Hedge Funds Weigh In On Protalix BioTherapeutics
Several hedge funds have recently made changes to their positions in PLX. Squarepoint Ops LLC raised its position in shares of Protalix BioTherapeutics by 673.3% in the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company's stock worth $161,000 after acquiring an additional 119,949 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Protalix BioTherapeutics in the 2nd quarter worth approximately $67,000. Virtu Financial LLC bought a new position in Protalix BioTherapeutics during the 3rd quarter valued at approximately $44,000. Sanctuary Advisors LLC purchased a new position in Protalix BioTherapeutics during the third quarter valued at $38,000. Finally, XTX Topco Ltd bought a new stake in Protalix BioTherapeutics in the third quarter worth $36,000. 16.53% of the stock is owned by hedge funds and other institutional investors.
Protalix BioTherapeutics Company Profile
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Recommended Stories
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 nuclear energy stocks poised to benefit from the coming nuclear boom. This report explores the companies leading the way in uranium supply, small modular reactors, and next-generation nuclear technologies. Download now to uncover key investment opportunities.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
